Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems.

Article Details

Citation

Sevrioukova IF, Poulos TL

Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems.

Dalton Trans. 2013 Mar 7;42(9):3116-26. doi: 10.1039/c2dt31833d. Epub 2012 Sep 27.

PubMed ID
23018626 [ View in PubMed
]
Abstract

Cytochromes P450 (CYPs) represent a diverse group of heme-thiolate proteins found in almost all organisms. CYPs share a common protein fold but differ in substrate selectivity and catalyze a wide variety of monooxygenation reactions via activation of molecular oxygen. Among 57 human P450s, the 3A4 isoform (CYP3A4) is the most abundant and the most important because it metabolizes the majority of administered drugs. A remarkable feature of CYP3A4 is its extreme promiscuity in substrate specificity and cooperative substrate binding, which often leads to undesirable drug-drug interactions and toxic side effects. Owing to its importance in drug development and therapy, CYP3A4 has been the most extensively studied mammalian P450. In this review we provide an overview on recent progress and remaining problems in the CYP3A4 research.

DrugBank Data that Cites this Article

Drug Enzymes
DrugEnzymeKindOrganismPharmacological ActionActions
ProgesteroneCytochrome P450 3A4ProteinHumans
Unknown
Substrate
Inducer
Details
Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
DrugsInteraction
Ripretinib
Nelfinavir
The serum concentration of Ripretinib can be increased when it is combined with Nelfinavir.
Ripretinib
Saquinavir
The serum concentration of Ripretinib can be increased when it is combined with Saquinavir.
Ripretinib
Nilotinib
The serum concentration of Ripretinib can be increased when it is combined with Nilotinib.
Ripretinib
Cobicistat
The serum concentration of Ripretinib can be increased when it is combined with Cobicistat.
Ripretinib
Conivaptan
The serum concentration of Ripretinib can be increased when it is combined with Conivaptan.